If you already pay for an advanced lab panel, a hormone prescriber and a longevity subscription or two, you may be asking whether a concierge practice for GLP-1 maintenance is worth $20,000 a year. Underneath sits the question you probably typed first. What happens after I reach my goal weight? Most programs are designed around the first months of treatment. Few are designed, staffed or priced for the year after.

This piece answers that question for one reader. You spend seriously on your health. You want nothing to do with a pill mill. You are comparing a concierge retainer with a membership that costs $299 a month. GoodLife Health is a clinician-led membership that manages GLP-1 maintenance over the long haul, for $299 a month in all fifty states. It sits between the $20,000 concierge practice and the $99 app, with quarterly labs and a clinician who stays. The reader described below is a composite drawn from common situations. No real patient is described.

Key Takeaways
  • After goal weight, a clinician decides from your markers whether the dose is held, lowered, changed or stopped.
  • Maintenance is a measuring problem that needs Apolipoprotein B (ApoB), Hemoglobin A1c (HbA1c) and Fasting Insulin read on a schedule.
  • The membership includes four cardiometabolic lab panels a year, read by a clinician who stays.
  • The fee is $299 a month at every dose, with nothing taken on the medication.
  • Medication goes to the pharmacy you choose at that pharmacy's own price.
  • A concierge practice may suit you better if you want full-scope primary care in person.

The year after the scale stops moving

The first phase of a GLP-1 is simple to describe. There is a starting dose and a schedule for raising it. There is a number on the scale that moves. Programs at every price advertise that phase because it is easy to show.

Goal weight is where the brochures stop. The questions that follow are harder. Should the dose stay where it is? Can it come down? Would an oral form make sense? What happened to your lipids and your fasting insulin while the weight came off? How does the hormone therapy you already take fit with any of it? Who will notice if something drifts over the next 12 months?

Here is the composite. Some years ago, an eight-minute visit ended with the word normal and a suggestion to eat fewer carbohydrates. You stopped waiting for the system and started paying for answers yourself. An advanced panel came from one company. Hormone therapy came from a second prescriber. The GLP-1 came from a third service. The weight has come down. Each of them sends you results. None of them reads what the others found.

You are close to your goal now. You can feel the gap. The service that prescribes the medication asks about your dose and your side effects. The hormone prescriber asks about sleep and symptoms. The lab company sends a report with colored bars and a list of general suggestions. Nobody owns the plan for next year. You are the only person holding the whole picture. You are also the one person in the arrangement who is not a clinician.

That is why the concierge practice looks like the answer. At $20,000 a year, it ought to be able to put everything in one place under one doctor. It may well do so. The worry underneath your question is more specific than access, though. You do not want to lose what you worked for. You do not want to be held at a high dose by anyone who earns more when you take more. You also do not want to pay a premium retainer and then discover that the annual panel is the same basic one the eight-minute visit ordered.

Those three worries point at one need. Maintenance needs someone who measures the right things on a schedule and decides the dose with nothing to gain from the answer. The rest of this piece explains why that matters. It sets out what we do about it and where a concierge practice may still be the better choice for you.

Goal weight turns the dose into a decision

Reaching goal weight ends the phase of treatment where the direction is obvious. While the dose is being raised, the plan points one way. After goal weight, there are several honest options. A clinician might hold the current dose. A clinician might lower it, change the form or, in some cases, stop the medication. Which of those fits you depends on your history, your markers and your own goals. We do not know in advance. Nobody who has not read your numbers can know either.

Clinical note

Whether a GLP-1 dose is held, lowered, changed or stopped after goal weight is a clinician's decision, made with the patient from their history and their current markers. No maintenance plan should be fixed before those markers are read.

That is the first thing worth understanding about maintenance. It is a run of decisions over many months. Any program that hands you a fixed plan for the year after goal weight, before anyone has measured you, is guessing on your behalf.

The second thing is that the decisions rest on more than the scale. Weight is one number. The cardiometabolic picture is several. Apolipoprotein B (ApoB), Lipoprotein (A) and Hs-CRP describe cardiovascular risk. Hemoglobin A1c (HbA1c) and Fasting Insulin describe how your body is handling glucose. The Lipid Panel, Standard and TSH With Reflex To Free T4 complete the picture. A scale reading cannot tell you whether any of them moved while the weight came off. A dose decision made without them is made on part of the information.

The third thing is cadence. A single annual draw shows a clinician one point. Four draws a year show a direction. When a dose is lowered or a form is changed, the direction is what a clinician needs to see. A quarterly panel shows a drift within 90 days. An annual panel may not show it for a year.

Reaching goal weight ends the part of treatment that is easy to sell and starts the part that has to be measured.

The fourth thing is the incentive. When a provider earns on the medication, a lower dose means lower revenue and a stopped prescription means a lost sale. That does not make every such provider dishonest. It does mean the structure leans one way at the moment you most want it to lean nowhere. A concierge practice may earn nothing on your medication at all. If you are weighing one, ask. Ask as well how often it draws the markers above after goal weight and who reads them.

The menu of branded options has also widened, which makes the decision more clinical. On April 1, 2026, the FDA approved Foundayo (orforglipron), a GLP-1 pill from Lilly. Novo Nordisk publishes its own self-pay prices through NovoCare. As listed in November 2026, Wegovy pens cost $199 a month for a new patient's first two fills through December 31, 2026, then $349 a month at every dose. The Wegovy pill is $149 a month at 1.5 mg, $199 at 4 mg and $299 at 9 mg and 25 mg. Those are the manufacturer's prices, published where anyone can read them. Whether any of these options suits you after goal weight is a decision for a clinician who has your numbers.

If you take hormone therapy, the picture has one more moving part. The February 2026 hormone relabeling changed the conversation about hormone therapy. That conversation belongs with the clinician who is also reading your lipids and your fasting insulin, because those markers and your hormones belong to one system. Three services that never speak to each other cannot hold that conversation for you.

What the membership does once you are there

GoodLife Health sits between the $20,000 concierge practice and the $99 app, with quarterly labs and a clinician who stays. After goal weight, that clinician manages the long haul.

The membership starts with testing. The clinician orders a cardiometabolic panel before anything is prescribed and orders another every quarter after. If you arrive close to goal weight on a medication prescribed elsewhere, the clinician reviews your current dose and decides with you what happens next.

The fee covers four cardiometabolic lab panels a year. Every result is in your hands. The same clinician reads each panel against the last one. The dose decisions after goal weight are therefore made from a trend. Between visits, you can message the care team. When a conversation needs a face, you meet by video.

The fee is the same whatever medication is indicated and whatever the dose. There is no molecule upcharge and no dose upcharge. When clinically indicated, medication is prescribed to the pharmacy you choose at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on it. A lower dose, a change of form or a decision to stop therefore changes nothing in what we earn. When your labs support a lower dose or stopping, that counts as a success.

The medication itself is branded and FDA-approved: Wegovy, Zepbound, Mounjaro or Ozempic for GLP-1, with oral options when they are indicated. We do not prescribe compounded GLP-1. The FDA states that compounded versions are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are marketed. A clinician's license carries the responsibility for what is prescribed. We would rather carry it with approved medicine.

Your hormone therapy can move to the same clinician. One clinician manages hormone therapy and GLP-1 together for one fee, with insulin, thyroid and lipids read in the same panel. Hormone therapy and thyroid medication are prescribed where indicated, to your pharmacy at its own price. For a reader who now pays three services that never compare notes, this is the part that closes the gap.

The definitive guide to Cardiometabolic Optimization explains why weight, hormones and lipids are treated as one system. What a direct primary care membership includes sets out the scope and its limits in detail.

Year one, side by side
$3,588
The membership for a year, with medication billed separately by your pharmacy
$20,000
A year at the concierge practice the membership is weighed against
4
Cardiometabolic lab panels a year in the membership
$299
The monthly fee at every dose

In year-one terms, the membership is $3,588 as priced in November 2026. Medication is billed separately by your pharmacy. The concierge practice in your comparison is $20,000 a year. We will not pretend the two buy the same thing. A good concierge practice may offer in-person care and a scope well beyond cardiometabolic medicine. What the membership offers is narrower and specific: quarterly markers, one clinician and a dose decided by someone with nothing to sell you.

The membership promises neither that you will keep the weight nor that a dose can be lowered. It does not replace insurance. It pairs with insurance for catastrophic cover and replaces the primary-care relationship within its scope, which is cardiometabolic care. Visits are by video. Whether a plan covers a medication is between you, your plan and your pharmacy. Prior authorization is the pharmacy's process. We do not claim to run it.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

Before you sign with anyone

Five things are worth doing this week, whether you join us, sign with a concierge practice or stay where you are.

  • Put every lab result from the past two years into one file, with the date and the lab's name on each.
  • Write down your current dose, who prescribed it and what it costs at your pharmacy.
  • Ask the concierge practice how often it draws Apolipoprotein B (ApoB), Hemoglobin A1c (HbA1c) and Fasting Insulin after goal weight and who reads them.
  • Ask whoever prescribes your GLP-1 what they earn if your dose goes down.
  • Ask who will manage your hormone therapy and your GLP-1 together.

If the answers come back specific and quarterly, you may not need us. If they come back vague, that is an answer too. Either way, you will walk into the next appointment with your own record in hand.

Who this is not for

This membership is the wrong choice if the lowest possible monthly price for a GLP-1 is what you are after. We prescribe only branded, FDA-approved medication. A $99 app and this membership answer different questions. The app answers how to get a prescription. The membership answers what your markers say about the dose. That answer takes testing and a clinician's time.

It is also the wrong choice if you want a promise about your weight a year from now. We make none. Anyone who makes one has not read your numbers.

If you want a physician in the room, a practice that handles every acute illness or one doctor for all of your care, a well-run concierge practice may serve you better. Our scope is cardiometabolic care, delivered by video and message. It is better to say so now than after the first two months.

The membership does not replace insurance, so keep your plan for the hospital. If you want testosterone promised before anyone has read your labs, look elsewhere. The clinician decides, where federal and state law allow. If you live outside the United States, we cannot care for you.

What you would be paying for

The membership is $299 a month. At sign-up, $598 is held on your card to cover the first two months. It is a hold and is charged only once a clinician accepts you into care. If the clinician cannot accept you, the hold is released and you are never charged. Once you are accepted, the first two months are charged and are non-refundable. From month three, the membership is month to month. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. The fee buys a cardiometabolic panel every quarter and a clinician who stays. Medication is prescribed to your pharmacy at its price, with nothing taken on it. In return, you get the diagnosis an eight-minute visit never produced and your markers followed over time. You do not repeat the eight-minute visit. We test first and treat second. We sell neither the drug nor the dose. If your goal weight is in sight, the dose decisions are close. A baseline drawn now gives the clinician who will make them something to compare against.

Related Reading

References

  1. NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
  2. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss